Talk with Mr Leon Wang, Executive Vice President, International & President AstraZeneca China – Swedish Chambers APAC Online Event 14 March 2022
For this Swedish Chambers APAC event, we welcomed Mr Leon Wang, Executive Vice President, International & President AstraZeneca China, who gave us an insight into AstraZeneca’s efforts to overcome the COVID-19 pandemic, its focus on harnessing the power of science, digital innovation and partnership to build more resilient healthcare systems in a post-pandemic world, and their determination to improve health for as many people in as many countries as possible.
Mr Peter Ling-Vannerus, Chief Representative, SEB Beijing, will moderate the conversation with Mr Wang.
About the speaker:
Mr Leon Wang Executive Vice-President, International and President AstraZeneca China
He is responsible for overall strategy driving sustainable growth across the International region, which includes China. Leon joined AstraZeneca China in March 2013 and was promoted to become President, AstraZeneca China in 2014. Under Leon’s leadership, China has become AstraZeneca’s second largest market worldwide and AstraZeneca has become the largest pharmaceutical company in China. In January 2017, Leon was promoted to Executive Vice-President, Asia Pacific Region. Prior to joining AstraZeneca, Leon held positions of increasing responsibility in marketing and business leadership at Roche, where he was a Business Unit Vice-President. In addition, Leon holds several positions in local trade associations and other prominent organisations in China. Leon holds an EMBA from China Europe International Business School, and a Bachelor of Arts from Shanghai International Studies University.
AstraZeneca develops, manufactures and sells pharmaceuticals and biotechnology products to treat disorders in the oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom, and its main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland).
